Financial Daily from THE HINDU group of publications
Friday, Jan 11, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Performance


Ranbaxy: A dose of US

Our Bureau

RANBAXY Laboratories Ltd, founded in 1961, had established its operations in the US in 1994 and launched its first prescription product, following FDA approvals in January 1998.

In September 1995, Ohm Laboratories was acquired for the dual role of providing manufacturing support for Ranbaxy Pharmaceuticals Inc's approved `abbreviated new drug application products', while developing its presence in the private label OTC (over-the-counter) market.

Send this article to Friends by E-Mail

Stories in this Section
New IIMT campus for course in hospitality


Zuari to buy out India Cements in Sri Vishnu
FIs open to divesting MRL stake in favour of Modis
Qualcomm may invest $200 m in Reliance Comm
Sugaronline.com changes hands
Tata Tea, Tetley integration process to start next month
UB to go in for buyback at South African beer co
Nestle group ups stake in Indian arm to 53.27 pc
Secretarial standard on board meetings -- ICSI guidelines aimed at harmonisation
Default on filing mandatory papers -- DCA to prosecute listed cos first
Special effects come to Bollywood
After pizzas, Amul plans foray into sugar
Sugartrade.com ties up with MDEX -- MoU to develop futures exchange
Post-APM sword hangs over RPL-IOC deal
Exult Inc deal with Hexaware, HCL
Miditech planning TV soaps, family dramas
Ranbaxy bullish on US subsidiaries
Ranbaxy: A dose of US
Maruti bid to push sales in N-E, East
CESC feels the heat on power supply cut
Allana Sons is top coffee exporter
Synergies-Dooray bags award
Digital GlobalSoft gets new Chairman
Nilekani crowned Infosys CEO -- Narayana Murthy is `Chief Mentor'
Virgin Air plans flight consolidation in India
MTNL game to take on rivals


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright © 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line